About this Journal
|Impact Factor: 3.0|
|Acceptance Rate: 29%|
|Time to final decision: 8 weeks|
|Online after acceptance: 13 days|
News & Highlights
Call for Papers
Anti-amyloid Drugs: A Therapeutical Revolution in Alzheimer’s Disease.
The Neurodegenerative Diseases Transformative Journal model supports authors and organizations in making a sustainable transition to Open Access, while enabling authors' publishing preferences.
For more information, refer to the journal's guidelines.
Neurodegenerative Diseases is Member of NPRC
The Neuroscience Peer Review Consortium (NPRC) is an alliance of neuroscience journals that share manuscript reviews with other NPRC members at the author's request. The NPRC system facilitates fast-track review and publication of neuroscience research, and reduces the burden on peer reviewers.
On the 1st of August 2023, a new cycle initiated for Neurodegenerative Diseases. We welcome Prof. Gilles Allali, head of the Leenaards Memory Centre – CHUV Lausanne, Switzerland, as the new Editor-in-Chief of Neurodegenerative Diseases. Our heartfelt thanks to Prof. Unschuld who led the Journal as Editor-in-Chief for the past 5 and a half years.
Read the Publisher's Note marking this change in leadership: New editorship of Neurodegenerative Diseases
And Prof. Allali’s editorial: A Pivotal Time